ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002

Prostate

Volumn 56, Issue 2, 2003, Pages 142-149

  Tørring, Niels ^a   Dagnæs Hansen, Frederik ^b   Sørensen, Boe Sandahl ^a   Nexø, Ebba ^a   Hynes, Nancy E ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Androgen; Apoptosis; EGF; ErbB1; LNCaP cells; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANDROGEN; CGP 59326; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; METRIBOLONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 (PHENYLAMINO) 7H PYRROLO(2,3 D)PYRIMIDINE; 4-(PHENYLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDINE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; LIGAND; MORPHOLINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANDROGEN RELEASE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; APOPTOSIS; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; GENETICS; MALE; METABOLISM; PROSTATE TUMOR;

ANDROGENS; APOPTOSIS; CELL DIVISION; CHROMONES; DRUG INTERACTIONS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; MALE; MORPHOLINES; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0042308761     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10245     Document Type: Article

References (41)

1. American Cancer Society. 2002. Cancer Facts & Figures - 2002.
2. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265.
3. Newling DW. The management of hormone refractory prostate cancer. Eur Urol 1996;29:69-74.
4. Tørring N, Jørgensen PE, Sørensen BS, Nexø E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha, and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-95.
5. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
6. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-184.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
8. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000;103:57-75.
9. Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J 1993;12:961-971.
10. Riese DJ II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-48.
11. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
13. Sherwood ER, Lee C. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995;13:290-296.
14. Myers RB, Kudlow JE, Grizzle WE. Expression of transforming growth factor-alpha, epidermal growth factor, and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Pathol 1993;6:733-737.
15. Harper ME, Goddard L, Glynne-Jones E, Wilson DW, Price-Thomas M, Peeling WB, Griffiths K. An immunocytochemical analysis of TGF alpha expression in benign and malignant prostatic tumors. Prostate 1993;23:9-23.
16. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
17. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988; 12:99-110.
18. Tørring N, Møller-Ernst Jensen K, Lund L, Nielsen JE, Djurhuus JC, Poulsen SS, Nexø E. Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: A placebo-controlled randomized study. BJU Int 2002;89:583-590.
19. Jørgensen PE, Eskildsen L, Nexø E. Adsorption of EGF receptor ligands to test tubes - a factor with implications for studies on the potency of these peptides. Scand J Clin Lab Invest 1999;59:191-197.
20. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565.
21. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
22. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Rev 2001;21:499-512.
23. Brandt R, Wong AM, Hynes NE. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 2001;20:5459-5465.
24. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995;15:1182-1191.
25. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-2723.
26. Simpson L, Parsons R. PTEN: Life as a tumor suppressor. Exp Cell Res 2001;264:29-41.
27. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-9559.
28. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 1999;59:1449-1453.
29. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897.
30. Schuurmans AL, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 1988;12:55-63.
31. Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H, Grizzle WE. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer 1999;82:424-429.
32. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-806.
33. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-2647.
34. Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 2000;148:385-397.
35. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol 2001;12(Suppl 1):9-13.
36. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-1925.
37. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-285.
38. Arai Y, Yoshiki T, Yoshida O. c-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer. Prostate 1997;30:195-201.
39. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC, Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7:2703-2711.
40. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
41. Ittmann MM. Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol Rep 1998;5:1329-1335.